Cell Signaling Technology Inc. (CST) is a new company founded in October 1999 by New England Biolabs. Composed of scientists from the NEB Cell Signaling Group, CST is committed to developing innovative tools for research in Signal Transduction.

CST offers a broad array of new reagents to assist in the discovery of how proteins are regulated and function within the cell. These cutting edge tools are designed to advance the understanding of Protein Function, and to open up new research directions in Neurobiology, Cancer Biology and basic Cell Biology. Scientists at CST have established a leadership position in the market for phospho-antibodies that are useful in detecting activity in discrete pathways that regulate growth and death in cells.

CST is committed to developing "smart" antibodies that by virtue of their binding specificity provide important biological information. These "smart" or activation state-specific antibodies reveal whether a protein and by inference its downstream signaling pathway are active or inactive. In pioneering the development of phosphorylation state-specific antibodies, our scientists have generated the first phospho-specific antibodies to many key signaling molecules including three major MAP kinases and Akt. Recently, the range of these antibodies has been extended to include cleavage-specific antibodies that monitor activity in pathways involving proteolysis, and antibodies that recognize other important post-translational modifications such as acetylation.

All of CST's reagents are produced with both the academic researcher and the scientist involved in drug discovery and proteomics in mind.